MarginsXMarginsX
Home › Markets › Health Care › RNAC

Cartesian Therapeutics Inc. (RNAC)

RNAC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.08
-4.25% on the day
Market cap
$185.5M
Micro cap
Revenue · 2025
$2.8M
-92.8% on 2024
Net income · 2025
-$130.3M
-4658.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/0001453687-26-000064-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRNAC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2016
SEC CIK0001453687
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.8M
Net income-$130.3M
Operating income-$143.4M
Net margin-4658.6%
Operating margin-5127.1%
Revenue growth-92.8%
Cash$125.1M
Total assets$296.4M
P/E (computed)Net income was not positive
P/S (computed)66.3×

Warning signs

Cash runway
16.6 months
$123.0M cash at September 30, 2026
Share count, 1 year
+17.3%
2025-10-31 to 2026-10-31 · +489.6% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$53K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$123.0M cash; operating cash flow -$22.2M a quarter.Report 2026-09-30
Shares outstanding30,503,005 (2026-10-31); 26,003,606 a year earlier; 155,204,182 three years earlier. 3y figure adjusted for split (1-for-30 overall).Cover page 2026-10-31
Reverse splits, 3 years1; latest 1-for-30 on 2024-04-05Source 2024-04-05
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $206K, sold $259K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$11.5M-$27.7M$123.0M$50.2M$1.0M10-Q 2026-11-05
Q2 2026
2026-06-30
$0$15.8M-$21.1M$147.6M$52.9M$1.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$78K-$39.2M-$22.1M$118.6MNo debt tags$1.8M10-Q 2026-04-30
Q4 2025
2025-12-31
$947K-$92.6M-$17.7M$125.1M$0$2.8M10-K 2026-03-09
Q3 2025
2025-09-30
$452K-$35.9M-$15.6M$143.4MNo debt tags$1.1M10-Q 2026-11-05
Q2 2025
2025-06-30
$298K$15.9M-$17.5M$160.3MNo debt tags$1.0M10-Q 2026-08-06
Q1 2025
2025-03-31
$1.1M-$17.7M-$23.1M$180.4MNo debt tags$34.2M10-Q 2026-04-30
Q4 2024
2024-12-31
-$759K-$10.3M-$7.0M$212.6MNo debt tags$38.9M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2025-01-10
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEF 14A2026-04-28

Source: SEC EDGAR submissions feed, 877 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.7%
1 month-3.3%
3 months-27.2%
Year to date-11.9%
1 year-12.2%
From 52-week high-40.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NATRNature's Sunshine Products Inc.$10.56+1.93%$183.0M
SLGLSol-Gel Technologies Ltd.$54.96-0.29%$179.9M
WHWKWhitehawk Therapeutics Inc.$3.01-1.63%$177.6M
TRDAEntrada Therapeutics Inc.$5.00-1.77%$195.8M
NGENNervGen Pharma Corp.$1.82-3.19%$195.9M
KROSKeros Therapeutics Inc.$10.03-2.62%$196.8M
KRROKorro Bio Inc.$12.71-6.61%$174.5M
IFRXInflaRx N.V.$1.18+0.85%$173.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier